Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
about
Assessment of platelet inhibition by point-of-care testing in neuroendovascular proceduresHigh residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceNightmare: Simultaneous Subacute Stent Thrombosis of Different New-Generation Drug-Eluting Stents in Multiple Coronary ArteriesEfficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled TrialsClopidogrel-Associated Thrombotic Thrombocytopenic Purpura following Endovascular Treatment of Spontaneous Carotid Artery Dissection.Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Effects of Ramadan fasting on platelet reactivity in diabetic patients treated with clopidogrel.Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of ClopidogrelGuided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapyMutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting.[Coronary intervention. 2012 update].A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD studyDiabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational studyCytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group.Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.Physician response to implementation of genotype-tailored antiplatelet therapy.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation.Safety and Efficacy of Intensified Antiplatelet Therapy in Patients Undergoing Neuroendovascular Procedures.The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions.Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrelPharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?Advances in the monitoring of anti-P2Y12 therapy.Platelet function monitoring and clopidogrel.Platelet function testing and tailored antiplatelet therapy.Monitoring aspirin and clopidogrel response: testing controversies and recommendations.Pharmacotherapy for the reduction of stent thrombosis.Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account.Cangrelor for treatment of arterial thrombosis.Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.Resistance to antiplatelet drugs: what progress has been made?
P2860
Q26823633-23A11F68-365C-45A4-9360-695809C11B90Q26824850-908EB19A-5D69-46E1-9A80-F4792FADEAA1Q28468703-3883945E-9A70-4979-9564-E1155EDB4E73Q28548148-632BE0CB-8DF0-4D00-BC6D-A92A54FA79ADQ33428029-87299B52-36A3-4BF1-832B-EFAAF94C108CQ33637840-2404FC6F-FFAA-4692-AEF5-B3699C196344Q33760007-0A034AAC-FDF3-4A41-A51D-2E5E9F16C32BQ33837665-EF144719-4609-4F22-8D7D-C4EC2A59D860Q33863833-6CEE0F7D-F504-4AFA-A5E9-33294B55490DQ33898876-869231C8-D7A6-41D9-A370-E2126DA15059Q34108764-7D823901-3640-4120-A479-115A4D9CE63FQ34180883-16AC26EF-31BB-4EFB-B77F-D06D8069F118Q35126038-33E712D4-AF79-4822-97EF-7CF608009B16Q35677083-643F673E-2D93-448A-80AF-6675DB417DE5Q35683705-D9D9309F-9DE8-4E2F-AA3E-DA5E7D4AE3AEQ35985453-4A9F2DBA-6A61-4B7E-AA8A-118F6187192CQ36039469-BD44D077-F34E-4044-B622-48EC5F343042Q36205878-EA79D339-FB4A-4678-AE97-FC37F5EBDCEAQ36216424-393CA516-561B-4574-ADD8-57AD563F474DQ36676028-9207662F-59DA-43E7-9FF3-93DFE9476CA7Q36688145-540CC597-9E8D-45D2-8362-F3764A76C213Q36822610-CE209208-20C2-4F9F-9CC6-0A0B9A5EE31EQ36984543-47EA067E-D6C8-43CF-8939-83368557E3ECQ37497555-66600527-A802-4B1A-BD9B-528D61541424Q37642212-C1AE6151-1291-440E-8CEF-A9F920546255Q37652931-2327CF5A-E019-4421-9B70-AEDDB8952770Q37664571-4ADC60A5-4068-423D-A121-BB3F23A8269DQ37692142-800AB8B3-2E6C-4BF8-A457-6745632AB44CQ37724614-60F6A5E8-CFF3-41B2-87A2-A7F781F48020Q37973457-6601FA85-E65A-4E83-BCF7-BA8E40D764CAQ38037121-718A1B2D-14F3-4935-A97C-87273435E6DDQ38068348-9B606D6A-73BF-4B2A-A60F-B8E59DB06EB2Q38094681-6E2FF382-09BE-4854-ADA9-EB2F9DFB52C6Q38099235-4E6DCFAA-13AC-4131-A22E-2E1DE41836BDQ38101963-AB3372BC-72CA-48B1-AA59-8063C19C8168Q38128171-4551CA53-BF9A-4F5B-A4A0-FFF83729BEF8Q38154612-71C06CE5-E146-47E7-8FB8-3B5496CF90E0Q38183489-A4221028-F407-4926-8C09-BEC0D5284619Q38243032-62925EBE-C1E1-4C4E-A813-9694AE21ED87Q38258270-B5219335-CED8-42F9-A095-1A5F2F5E0F6A
P2860
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Platelet reactivity and cardio ...... s and Safety (GRAVITAS) trial.
@en
type
label
Platelet reactivity and cardio ...... s and Safety (GRAVITAS) trial.
@en
prefLabel
Platelet reactivity and cardio ...... s and Safety (GRAVITAS) trial.
@en
P2093
P1433
P1476
Platelet reactivity and cardio ...... s and Safety (GRAVITAS) trial.
@en
P2093
Christopher P Cannon
Dominick J Angiolillo
Elizabeth Lillie
Jean-François Tanguay
Matthew J Price
Paul S Teirstein
Steven V Manoukian
P304
P356
10.1161/CIRCULATIONAHA.111.029165
P407
P577
2011-08-29T00:00:00Z